Physician profile
Abbey Strauss
NPI 1124005913
$13,006.61
in general payments reported to CMS, 2019-2025
29 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,195 · 2020: $1,595 · 2021: $842 · 2022: $1,459 · 2023: $2,251 · 2024: $2,379 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,916.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,147.29 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,737.58 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,508.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,052.55 | 2019-2024 | Rexulti, Abilify Asimtufii |
| Allergan, INC. | $949.84 | 2019-2020 | |
| Abbvie INC. | $732.45 | 2021-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $575.41 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $539.51 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $418.41 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $406.19 | 2019-2024 | Spravato |
| Lundbeck LLC | $361.13 | 2019-2021 | |
| Axsome Therapeutics, INC. | $327.95 | 2023-2024 | Auvelity |
| Almatica Pharma LLC | $201.62 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $189.10 | 2019-2023 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $147.63 | 2020-2024 | Fanapt, Hetlioz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $122.50 | 2024 | Xelstrym |
| Livanova USA, INC. | $108.97 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Avanir Pharmaceuticals, INC. | $101.09 | 2019 | |
| Lilly USA, LLC | $90.17 | 2025 | Kisunla |
| Tms Neurohealth Centers INC. | $80.04 | 2025 | Tms Neurohealth Centers INC. |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.92 | 2019 | |
| Eisai INC. | $30.27 | 2020 | |
| Merck Sharp & Dohme LLC | $22.29 | 2023 | Belsomra |
| Adlon Therapeutics L.P. | $20.90 | 2021 | |
| Neos Therapeutics, LP | $20.48 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.43 | 2022 | |
| Alfasigma USA, INC. | $17.12 | 2021 | |
| Harmony Biosciences LLC | $14.81 | 2020 | |
| Tempus Ai, INC | $14.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbey Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.